



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Tenalisib

Item No. 30949

CAS Registry No.: 1639417-53-0
Formal Name: 3-(3-fluorophenyl)-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4H-1-benzopyran-4-one
Synonym: RP 6530
MF: C₂₃H₁₈FN₅O₂
FW: 415.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tenalisib is supplied as a solid. A stock solution may be made by dissolving the tenalisib in the solvent of choice, which should be purged with an inert gas. Tenalisib is soluble (≥10 mg/ml) in DMSO and sparingly soluble (1-10 mg/ml) in ethanol.

Description

Tenalisib is an inhibitor of PI3Kδ and PI3Kγ (IC₅₀s = 24.5 and 33.2 nM, respectively).¹ It is greater than 300- and 120-fold selective for PI3Kδ and PI3Kγ, respectively, over PI3Kα and PI3Kβ. Tenalisib (10 μM) induces cell death in L-540, KM-H2, and L-428 Hodgkin lymphoma cells. It induces cell cycle arrest at the G₀/G₁ phase in the same cells. *In vivo*, tenalisib reduces tumor growth and vasculature, induces tumor necrosis, and induces the M₁ phenotype in tumor-associated macrophages (TAMs) in an L-540 mouse xenograft model.

Reference

1. Locatelli, S.L., Careddu, G., Serio, S., *et al.* Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530. *Clin. Cancer Res.* 25(3), 1098-1112 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/04/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM